Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C.

Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.

PMID:
20100092
2.

Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.

van Lelyveld SF, Nijhuis M, Baatz F, Wilting I, van den Bergh WM, Kurowski M, de Jong D, Hoepelman AI, Wensing AM.

Clin Infect Dis. 2010 Feb 1;50(3):387-90. doi: 10.1086/649874.

PMID:
20047481
3.

Treatment of HIV infection: Swedish recommendations 2009.

Josephson F, Albert J, Flamholc L, Gisslén M, Karlström O, Moberg L, Navér L, Svedhem V, Svennerholm B, Sönnerborg A; Swedish Medical Products Agency.; Swedish Reference Group for Antiviral Therapy..

Scand J Infect Dis. 2009;41(11-12):788-807. doi: 10.3109/00365540903214322. Review.

PMID:
19922061
4.

Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment.

Garvey LJ, Everitt A, Winston A, Mackie NE, Benzie A.

AIDS. 2009 Jul 17;23(11):1443-4. doi: 10.1097/QAD.0b013e32832d077c. No abstract available.

PMID:
19564723
5.

Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia.

Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R.

PLoS Pathog. 2009 Apr;5(4):e1000395. doi: 10.1371/journal.ppat.1000395. Epub 2009 Apr 24.

6.

Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.

Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, Yiannoutsos CT, Spudich S, Price RW.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):544-52. doi: 10.1097/QAI.0b013e318162754f.

7.

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group..

Arch Neurol. 2008 Jan;65(1):65-70. doi: 10.1001/archneurol.2007.31.

8.

Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.

Edén A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M.

J Infect Dis. 2007 Dec 15;196(12):1779-83. doi: 10.1086/523648.

PMID:
18190258
9.

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):168-73.

10.

Updated research nosology for HIV-associated neurocognitive disorders.

Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE.

Neurology. 2007 Oct 30;69(18):1789-99. Epub 2007 Oct 3.

11.

The prevalence and incidence of neurocognitive impairment in the HAART era.

Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ.

AIDS. 2007 Sep 12;21(14):1915-21.

PMID:
17721099
12.

CD4+ count-guided interruption of antiretroviral treatment.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group., El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C.

N Engl J Med. 2006 Nov 30;355(22):2283-96.

13.

Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.

Spudich S, Lollo N, Liegler T, Deeks SG, Price RW.

J Infect Dis. 2006 Dec 15;194(12):1686-96. Epub 2006 Nov 3.

PMID:
17109340
14.

Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW.

BMC Infect Dis. 2005 Nov 2;5:98.

15.

Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.

Mellgren A, Antinori A, Cinque P, Price RW, Eggers C, Hagberg L, Gisslén M.

Antivir Ther. 2005;10(6):701-7.

PMID:
16218168
16.

Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection.

Gisslén M, Rosengren L, Hagberg L, Deeks SG, Price RW.

AIDS Res Ther. 2005 Aug 18;2:6.

17.

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M.

Scand J Infect Dis. 2004;36(11-12):823-8.

PMID:
15764168
19.

Changing incidence of central nervous system diseases in the EuroSIDA cohort.

d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J; EuroSIDA Study Group..

Ann Neurol. 2004 Mar;55(3):320-8.

PMID:
14991809
20.

Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance.

Bestetti A, Presi S, Pierotti C, Bossolasco S, Sala S, Racca S, Carrera P, Lazzarin A, Cinque P.

J Neurovirol. 2004;10 Suppl 1:52-7.

PMID:
14982740

Supplemental Content

Support Center